IASLC 关于晚期 NSCLC 液体活检的共识声明(2021 更新)
国际肺癌研究协会(IASLC)组织多学科国际专家更新 2018 年液体活检共识,聚焦晚期 NSCLC 分子检测中「血浆优先」与「组织优先」的抉择。声明汇总血浆循环肿瘤 DNA 检测技术进展与 FDA 批准的两项检测,给出何时选择何种检测及结果解读的循证推荐。
要点
- 晚期 NSCLC 分子分型中液体活检可作组织检测的替代来源。
- 血浆 ctDNA 是实体瘤中研究最充分、应用最广的替代方法。
- 共识就「血浆优先」与「组织优先」策略给出循证推荐。
核心结论
- IASLC 多学科国际专家团队以共识形式更新 2018 年声明,补充液体活检在晚期 NSCLC 治疗决策中的新考量。
主要发现
- 血浆循环肿瘤 DNA 是包括 NSCLC 在内的实体瘤中研究最广泛、最常采用的组织肿瘤基因分型替代方法。
- 液体活检最早进入临床实践用于 NSCLC 的 EGFR 突变检测。
- 过去数年血浆二代测序临床应用增长,美国 FDA 已批准两项不同的循环肿瘤 DNA 分析检测。
关键数值与推荐
- 共识推荐涉及晚期 NSCLC 分子检测中何时开具何种检测以及如何解读结果。
- 共识讨论了「血浆优先」与「组织优先」两种分子检测策略。
临床怎么用
- 对晚期 NSCLC 可考虑以血浆 ctDNA 液体活检替代或补充组织基因分型以支持靶向治疗选择。
- 按 IASLC 共识推荐决定分子检测的先后顺序(血浆优先或组织优先)并规范解读结果。
局限性
- 肿瘤组织仍是这些分子分析历史上「被接受的标准」生物标本,但存在明显固有局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although precision medicine has had a mixed impact on the clinical management of patients with advanced-stage cancer overall, for NSCLC, and more specifically for lung adenocarcinoma, the advances have been dramatic, largely owing to the genomic complexity and growing number of druggable oncogene drivers. Furthermore, although tumor tissue is historically the "accepted standard" biospecimen for these molecular analyses, there are considerable innate limitations. Thus, liquid biopsy represents a practical alternative source for investigating tumor-derived somatic alterations. Although data are most robust in NSCLC, patients with other cancer types may also benefit from this minimally invasive approach to facilitate selection of targeted therapies. The liquid biopsy approach includes a variety of methodologies for circulating analytes. From a clinical point of view, plasma circulating tumor DNA is the most extensively studied and widely adopted alternative to tissue tumor genotyping in solid tumors, including NSCLC, first entering clinical practice for detection of EGFR mutations in NSCLC. Since the publication of the first International Association for the Study of Lung Cancer (IASLC) liquid biopsy statement in 2018, several additional advances have been made in this field, leading to changes in the therapeutic decision-making algorithm for advanced NSCLC and prompting this 2021 update. In view of the novel and impressive technological advances made in the past few years, the growing clinical application of plasma-based, next-generation sequencing, and the recent Food and Drug and Administration approval in the United States of two different assays for circulating tumor DNA analysis, IASLC revisited the role of liquid biopsy in therapeutic decision-making in a recent workshop in October 2020 and the question of "plasma first" versus "tissue first" approach toward molecular testing for advanced NSCLC. Moreover, evidence-based recommendations from IASLC provide an international perspective on when to order which test and how to interpret the results. Here, we present updates and additional considerations to the previous statement article as a consensus from a multidisciplinary and international team of experts selected by IASLC.
引用
- Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID: 34246791. doi:10.1016/j.jtho.2021.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。